AYTU BIOPHARMA, INC Business Acquisition, Pro Forma Net Income (Loss)
AYTU BIOPHARMA, INC (AYTU) reported Business Acquisition, Pro Forma Net Income (Loss) of -$92.47 million for the 9-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2022-05-16
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for the quarter ending 2022-03-31 was -$53.07M.
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for the quarter ending 2021-12-31 was -$11.55M.
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for the quarter ending 2021-09-30 was -$27.85M.
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for the quarter ending 2021-06-30 was -$19.00M.
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for fiscal 2021 was -$74.71M.
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for fiscal 2020 was -$35.32M.
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for fiscal 2019 was -$37.94M.
- AYTU BIOPHARMA, INC business acquisition, pro forma net income (loss) for fiscal 2015 was -$8.31M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-03-31 | -$53.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | -$64.62M derived: sum of 2 quarters · filed 2022-05-16 | -$92.47M 10-Q · filed 2022-05-16 | -$111.47M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2021-12-31 | -$11.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$39.40M 10-Q · filed 2022-02-14 | -$58.40M derived: sum of 3 quarters · filed 2022-02-14 | -$91.07M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2021-09-30 | -$27.85M 10-Q · filed 2021-11-15 | -$46.85M derived: sum of 2 quarters · filed 2021-11-15 | -$79.52M derived: sum of 3 quarters · filed 2022-05-16 | -$93.34M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2021-06-30 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | -$51.67M derived: sum of 2 quarters · filed 2022-05-16 | -$65.49M derived: sum of 3 quarters · filed 2022-05-16 | -$74.71M 10-K · filed 2021-09-28 | |||
| 2021-03-31 | -$32.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | -$46.49M derived: sum of 2 quarters · filed 2022-05-16 | -$55.71M 10-Q · filed 2022-05-16 | -$59.35M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$13.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$23.04M 10-Q · filed 2022-02-14 | -$26.67M derived: sum of 3 quarters · filed 2022-02-14 | -$40.47M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | -$9.22M 10-Q · filed 2021-11-15 | -$12.85M derived: sum of 2 quarters · filed 2021-11-15 | -$26.65M derived: sum of 3 quarters · filed 2021-11-15 | -$29.10M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | -$17.43M derived: sum of 2 quarters · filed 2021-09-28 | -$19.89M derived: sum of 3 quarters · filed 2021-09-28 | -$35.32M 10-K · filed 2021-09-28 | -$16.38M 10-K · filed 2020-10-06 | ||
| 2020-03-31 | -$13.80M 10-Q · filed 2021-05-17 | -$5.85M 10-Q · filed 2020-05-15 | -$16.25M derived: sum of 2 quarters · filed 2021-05-17 | -$31.69M 10-Q · filed 2021-05-17 | -$18.20M 10-Q · filed 2020-05-15 | -$45.24M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | -$2.45M 10-Q · filed 2021-02-11 | -$11.26M 10-Q · filed 2021-02-11 | -$31.44M derived: sum of 3 quarters · filed 2021-02-11 | -$40.18M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2019-09-30 | -$8.26M 10-Q · filed 2020-11-12 | -$28.99M derived: sum of 2 quarters · filed 2020-11-12 | -$37.73M derived: sum of 3 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | -$20.73M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | -$29.48M derived: sum of 2 quarters · filed 2020-10-06 | -$37.94M 10-K · filed 2020-10-06 | ||||
| 2019-03-31 | -$8.74M 10-Q · filed 2020-05-15 | -$17.21M 10-Q · filed 2020-05-15 | |||||
| 2015-06-30 | -$8.31M 10-K · filed 2015-09-28 | ||||||
| 2014-06-30 | -$6.10M 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |